Combination therapy includes antibodies binding tumor associated antigens

A pharmaceutical composition comprising at least one antibody or binding fragment thereof binding to a tumor associated antigen (TAA) and at least one agonist antibody or fragment thereof agonistic binding anti- CD40, wherein said at least one antibody binding or fragment thereof binding TAA joins NY-ESO-1and wherein said at least one antibody or binding fragment thereof binding TAA comprises a region of the variable light chain comprises a CDR1 SEQ ID NO: 8, a CDR2 of SEQ ID NO: 9 and a CDR3 of SEQ ID NO: 10 and a region of the variable heavy chaincomprising a CDR1 of SEQ ID NO: 5, CDR2 of SEQ ID NO: 6 and a CDR3 of SEQ ID NO: 7.